The UK National Institute for Health and Care Excellence (NICE) has reached its final decision on two Alzheimer’s treatments, denying their use on the NHS due to the therapies not providing “good valu...

BioNTech plans to buy mRNA-based cancer immunotherapy and infectious disease vaccine company CureVac in an all-stock deal, the companies said Thursday.

BioNTech plans to buy mRNA-based cancer immunotherapy and infectious disease vaccine company CureVac in an all-stock deal, the companies said Thursday.

Schrödinger said its experimental MALT1 inhibitor showed early signs of safety and efficacy in an ongoing Phase 1 trial.

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a collaboration wi...

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline

BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive $1.5 billion upfront from Bristol Myers Squibb to co-deve...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and...

Budget documents for Congress provide the most detailed look yet at how the Trump Administration hopes to reshape the National Institutes of Health.

Is Biopharma Doing Enough to Advance Novel Targets?

What if the key to treating chronic and age-related diseases has been hidden in plain sight, within…

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B funding to get into the clinic. The transatlantic outfit's experimental medicines...

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least one analyst said amount to a best-case outcome. ...

Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according to LinkedIn posts from the nimble company's co-founders.

Orionis Biosciences has announced a second collaboration with Genentech, worth $105 million upfront and up to $2 billion in potential milestone payments, to develop small-molecule glue medicines for o...

Octagon Therapeutics has thrown in the towel. | Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program a...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio.  | Eli Lilly is paying $13 mill...

Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid a bleak biotech market.

HAYA Therapeutics is using its unparalleled regulatory genome atlas and innovative proprietary platform to identify novel long non-coding RNAs and develop drug candidates that return diseased cells ba...

iNearly two dozen crypto wallets acquired more than 100,000 $TRUMP meme coins, worth roughly $100 million, after the team said top buyers could join the president for dinner.

STAT is tracking, day by day, what's happened in the words of science and health during the first months of the Trump administration.

During Thursday’s first-quarter earnings call, Chris Boerner made his strongest comments yet that Bristol Myers intends to be active at the dealmaking table this year.

A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A. The startup, named Grove Biopharma, weathered the pandemic and, after ...

The last bits of fellowship and ingenuity on the web are being swept away by a tide of so-called artificial intelligence

Alis Biosciences then plans to list and offer big investors an easy way to spread their bets

DOGE is putting new curbs on billions of dollars in federal grants, requiring officials to manually review and approve payments that were previously routine.

While much of the country is focused on the spiraling measles outbreak, experts warn that whooping cough and other preventable diseases could get much worse with falling vaccination rates and Trump’s ...

BigHat Biosciences has added another pharma partner and more cash to its balance sheet as the antibody specialist prepares to enter the clinic next year. The Bay Area startup will ...

Port Therapeutics and other early biotech startups face funding challenges as investors prefer clinical-stage companies, with Q1 2025 seeing lowest startup funding in decade.

Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, and includes 340B program changes for EpiPens and insulin.

The funding pause amid civil rights investigations into both universities sharply escalates the Trump administration’s campaign against elite colleges.

A scrappy team of drug developers has come together to create new medicines for patients with autoimmune diseases and allergies. They're going after the bustling subfield of Graves' disease and ...

A congressional commission is advocating for a $15 billion federal investment in America’s biotechnology sector, warning that the US could soon be eclipsed by China in a key frontier of ...

In light of the extremely challenging financial markets and our strong conviction in the value of our clinical programs, we, like so many others, have been forced to take steps to extend our cash runw...

To make sense of the stock selloff that started late last week, Endpoints News’ Max Bayer and Drew Armstrong spoke to Leerink Partners senior managing director David Risinger, who has been working on ...

At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting for nearly a third of those rounds. | At least 63 biopharma layoff rounds w...